



---

## Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

---

Correction to: *Nature Communications*  
<https://doi.org/10.1038/s41467-021-23912-4>,  
published online 17 June 2021

<https://doi.org/10.1038/s41467-022-33355-0>

Published online: 23 September 2022



---

Kamrine E. Poels , Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi , Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu & Franziska Michor

---

The original version of this Article contained an error in Fig. 1b, in which the mathematics were replaced by random symbols. In addition, the original version of this Article contained an error in Fig. 4, in which the shading representing predictions and interquartile ranges from mathematical modelling predictions was missing. This has been corrected in both the PDF and HTML versions of the Article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022